117 related articles for article (PubMed ID: 16951398)
1. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
2. Individual Irinotecan Therapy Under the Guidance of Pre-Treated
Lv H; Nie C; He Y; Chen B; Liu Y; Zhang J; Chen X
Technol Cancer Res Treat; 2024; 23():15330338241236658. PubMed ID: 38497131
[No Abstract] [Full Text] [Related]
3. Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
de With M; van Doorn L; Kloet E; van Veggel A; Matic M; de Neijs MJ; Oomen-de Hoop E; van Meerten E; van Schaik RHN; Mathijssen RHJ; Bins S
Clin Pharmacokinet; 2023 Nov; 62(11):1589-1597. PubMed ID: 37715926
[TBL] [Abstract][Full Text] [Related]
4. Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity.
Riera P; Salazar J; Virgili AC; Tobeña M; Sebio A; Gallano P; Barnadas A; Páez D
Br J Clin Pharmacol; 2018 Jun; 84(6):1389-1392. PubMed ID: 29504153
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of UGT1A1 and CYP3A Genotyping and Single-Point Irinotecan and Metabolite Concentrations as Predictors of the Occurrence of Adverse Events in Cancer Treatment.
Basso J; Schwartsmann G; Ibaldi MR; Schaefer VD; Pavei CC; Hahn RZ; Antunes MV; Linden R
J Gastrointest Cancer; 2023 Jun; 54(2):589-599. PubMed ID: 35710870
[TBL] [Abstract][Full Text] [Related]
6. Molecular Genetics External Quality Assessment Pilot Scheme for Irinotecan-Related UGT1A1 Genotyping in China.
Yi L; Lin G; Zhang K; Wang L; Zhang R; Xie J; Li J
PLoS One; 2016; 11(1):e0148081. PubMed ID: 26820647
[TBL] [Abstract][Full Text] [Related]
7. Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
Nakano S; Yuki S; Kawamoto Y; Nakatsumi H; Ando T; Kajiura S; Yoshikawa A; Harada K; Hatanaka K; Tanimoto A; Ishiguro A; Honda T; Dazai M; Sasaki T; Sakamoto N; Komatsu Y
Int J Clin Oncol; 2020 Oct; 25(10):1800-1806. PubMed ID: 32666389
[TBL] [Abstract][Full Text] [Related]
8. Hepatic activation of irinotecan predicts tumour response in patients with colorectal liver metastases treated with DEBIRI: exploratory findings from a phase II study.
Jones RP; Sutton P; Greensmith RM; Santoyo-Castelazo A; Carr DF; Jenkins R; Rowe C; Hamlett J; Park BK; Terlizzo M; O'Grady E; Ghaneh P; Fenwick SW; Malik HZ; Poston GJ; Kitteringham NR
Cancer Chemother Pharmacol; 2013 Aug; 72(2):359-68. PubMed ID: 23756919
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms and emerging strategies for irinotecan-induced diarrhea.
Xu S; Lan H; Huang C; Ge X; Zhu J
Eur J Pharmacol; 2024 Jul; 974():176614. PubMed ID: 38677535
[TBL] [Abstract][Full Text] [Related]
10. Randomized double-blind, placebo-controlled multicenter phase III study of prevention of irinotecan-induced diarrhea by a probiotic mixture containing Bifidobacterium BB-12
Mego M; Danis R; Chovanec J; Jurisova S; Bystricky B; Porsok S; Konkolovsky P; Vaclav V; Wagnerova M; Streško M; Brezinova B; Rečková M; Sutekova D; Pazderova N; Novisedlakova M; Zomborska E; Ciernikova S; Svetlovska D; Drgona L
Front Oncol; 2023; 13():1168654. PubMed ID: 37601667
[TBL] [Abstract][Full Text] [Related]
11. Development of a physiologically based pharmacokinetic model to predict irinotecan disposition during inflammation.
Tao G; Chityala PK; Li L; Lin Z; Ghose R
Chem Biol Interact; 2022 Jun; 360():109946. PubMed ID: 35430260
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel carboxylesterase 2 inhibitors for the treatment of delayed diarrhea and ulcerative colitis.
Cao Z; Liu Y; Chen S; Wang W; Yang Z; Chen Y; Jiao S; Huang W; Chen L; Sun L; Li Z; Zhang L
Biochem Pharmacol; 2023 Sep; 215():115742. PubMed ID: 37567318
[TBL] [Abstract][Full Text] [Related]
13. [Delayed diarrhea induced by irinotecan: from the perspective of gut microbiota].
Zhang ZY; Duan LP
Zhonghua Nei Ke Za Zhi; 2024 May; 63(5):507-511. PubMed ID: 38715491
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation studies of novel carboxylesterase 2 inhibitors for the treatment of irinotecan-induced delayed diarrhea.
Yang Z; Cao Z; Wang W; Chen Y; Huang W; Jiao S; Chen S; Chen L; Liu Y; Mao J; Zhang L; Li Z
Bioorg Chem; 2023 Sep; 138():106625. PubMed ID: 37300962
[TBL] [Abstract][Full Text] [Related]
15. Optimized rat models better mimic patients with irinotecan-induced severe diarrhea.
Zheng Z; Du T; Gao S; Yin T; Li L; Zhu L; Singh R; Sun R; Hu M
Toxicol Mech Methods; 2024 Jun; 34(5):572-583. PubMed ID: 38390772
[TBL] [Abstract][Full Text] [Related]
16. Revisiting
Emery LP; Brooks GA
JCO Oncol Pract; 2022 Apr; 18(4):281-282. PubMed ID: 35108028
[No Abstract] [Full Text] [Related]
17. Clinical Study on Prevention of Irinotecan-Induced Delayed-Onset Diarrhea by Hot Ironing with Moxa Salt Packet on Tianshu and Shangjuxu.
Lai X; Wang A
Emerg Med Int; 2022; 2022():6587884. PubMed ID: 35912389
[TBL] [Abstract][Full Text] [Related]
18. Development of visual predictive checks accounting for multimodal parameter distributions in mixture models.
Arshad U; Chasseloup E; Nordgren R; Karlsson MO
J Pharmacokinet Pharmacodyn; 2019 Jun; 46(3):241-250. PubMed ID: 30968312
[TBL] [Abstract][Full Text] [Related]
19. Retracted: Clinical Study on Prevention of Irinotecan-Induced Delayed-Onset Diarrhea by Hot Ironing with Moxa Salt Packet on Tianshu and Shangjuxu.
International EM
Emerg Med Int; 2024; 2024():9814198. PubMed ID: 38298940
[TBL] [Abstract][Full Text] [Related]
20. Efficiency of Protective Interventions on Irinotecan-Induced Diarrhea: A Systematic Review and Meta-Analysis.
He Y; Wu L; Qi X; Wang X; He B; Zhang W; Zhao W; Deng M; Xiong X; Wang Y; Liang S
Integr Cancer Ther; 2024; 23():15347354241242110. PubMed ID: 38567795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
